Literature DB >> 21934653

Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8.

Catherine L Watkins1, Edward J Sayers, Chris Allender, David Barrow, Christopher Fegan, Paul Brennan, Arwyn T Jones.   

Abstract

Delivering apoptosis inducing peptides to cells is an emerging area in cancer and molecular therapeutics. Here, we have identified an alternative mechanism of action for the proapoptotic chimeric peptide D-NuBCP-9-r8. Integral to D-NuBCP-9-r8 is the Nur-77-derived D-isoform sequence fsrslhsll that targets Bcl-2, and the cell-penetrating peptide (CPP) octaarginine (r8) that is required for intracellular delivery. We find that the N-terminal phenylalanine of fsrslhsll acts in synergy with the cell-penetrating moiety to enhance peptide uptake at low nontoxic levels and cause rapid membrane blebbing and cell necrosis at higher (IC(50)) concentrations. These effects were not observed when a single phenylalanine-alanine mutation was introduced at the N-terminus of D-NuBCP-9-r8. Using primary samples from chronic lymphocytic leukemia (CLL) patients and cancer cell lines, we show that NuBCP-9-r8 induced toxicity, via membrane disruption, is independent of Bcl-2 expression. Overall, this study demonstrates a new mechanism of action for this peptide and cautions its use as a highly specific entity for targeting Bcl-2. For delivery of therapeutic peptides the work emphasizes that key amino acids in cargo, located several residues away from the cell-penetrating sequence, can significantly influence their cellular uptake and mode of action.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21934653      PMCID: PMC3232455          DOI: 10.1038/mt.2011.175

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  26 in total

Review 1.  Cell-penetrating peptides and antimicrobial peptides: how different are they?

Authors:  Sónia Troeira Henriques; Manuel Nuno Melo; Miguel A R B Castanho
Journal:  Biochem J       Date:  2006-10-01       Impact factor: 3.857

2.  Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells.

Authors:  Gisela Tünnemann; Robert M Martin; Simone Haupt; Christoph Patsch; Frank Edenhofer; M Cristina Cardoso
Journal:  FASEB J       Date:  2006-09       Impact factor: 5.191

Review 3.  Cell-penetrating peptides as delivery vehicles for biology and medicine.

Authors:  Kelly M Stewart; Kristin L Horton; Shana O Kelley
Journal:  Org Biomol Chem       Date:  2008-04-15       Impact factor: 3.876

4.  Temperature-, concentration- and cholesterol-dependent translocation of L- and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells.

Authors:  Marjan M Fretz; Neal A Penning; Saly Al-Taei; Shiroh Futaki; Toshihide Takeuchi; Ikuhiko Nakase; Gert Storm; Arwyn T Jones
Journal:  Biochem J       Date:  2007-04-15       Impact factor: 3.857

5.  Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.

Authors:  Saïd Abes; Hong M Moulton; Philippe Clair; Paul Prevot; Derek S Youngblood; Rebecca P Wu; Patrick L Iversen; Bernard Lebleu
Journal:  J Control Release       Date:  2006-09-30       Impact factor: 9.776

Review 6.  Bcl-2 family proteins and cancer.

Authors:  K W Yip; J C Reed
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

Review 7.  Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.

Authors:  Avi Ashkenazi
Journal:  Nat Rev Drug Discov       Date:  2008-11-07       Impact factor: 84.694

8.  Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin.

Authors:  C Pepper; R Ward; T T Lin; P Brennan; J Starczynski; M Musson; C Rowntree; P Bentley; K Mills; G Pratt; C Fegan
Journal:  Leukemia       Date:  2007-02-08       Impact factor: 11.528

9.  A short Nur77-derived peptide converts Bcl-2 from a protector to a killer.

Authors:  Siva Kumar Kolluri; Xiuwen Zhu; Xin Zhou; Bingzhen Lin; Ya Chen; Kai Sun; Xuefei Tian; James Town; Xihua Cao; Feng Lin; Dayong Zhai; Shinichi Kitada; Frederick Luciano; Edmond O'Donnell; Yu Cao; Feng He; Jialing Lin; John C Reed; Arnold C Satterthwait; Xiao-kun Zhang
Journal:  Cancer Cell       Date:  2008-10-07       Impact factor: 31.743

10.  Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.

Authors:  Hong M Moulton; Michelle H Nelson; Susie A Hatlevig; Muralimohan T Reddy; Patrick L Iversen
Journal:  Bioconjug Chem       Date:  2004 Mar-Apr       Impact factor: 4.774

View more
  4 in total

1.  Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9.

Authors:  Manoj Kumar; Dikshi Gupta; Gurpal Singh; Sapna Sharma; Madhusudan Bhat; C K Prashant; A K Dinda; Surender Kharbanda; Donald Kufe; Harpal Singh
Journal:  Cancer Res       Date:  2014-04-16       Impact factor: 12.701

2.  Concomitant Delivery of Paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy.

Authors:  Dikshi Gupta; Manoj Kumar; Priyanka Tyagi; Sumeet Kapoor; Amit Tyagi; Tarani Kanta Barman; Surender Kharbanda; Donald Kufe; Harpal Singh
Journal:  Nanomedicine       Date:  2018-04-08       Impact factor: 5.307

3.  Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2.

Authors:  Rania Hamdy; Samia A Elseginy; Noha I Ziedan; Mohamed El-Sadek; Elsaid Lashin; Arwyn T Jones; Andrew D Westwell
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

4.  LXXLL peptide converts transportan 10 to a potent inducer of apoptosis in breast cancer cells.

Authors:  Kairit Tints; Madis Prink; Toomas Neuman; Kaia Palm
Journal:  Int J Mol Sci       Date:  2014-04-03       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.